Jiangsu Recbio Technology Co., Ltd.

2179

CNE1000057K9

Pharmaceuticals

End-of-day quote Hong Kong S.E. Other stock markets 03:30:00 20/05/2024 am IST			5-day change	1st Jan Change
9.2 ^CNY	-0.54%		0.00%	-15.29%

08/05	Jiangsu Recbio Technology Co., Ltd. Approves Election of Wang Ruwei as A Non-Executive Director	CI
27/03	Jiangsu Recbio Technology Co., Ltd. and Shanghai Rongsheng Biotech Co.,Ltd. Sign Strategic Cooperation Agreement on the New Adjuvant Vaccine Project	CI

Jiangsu Recbio Technology Co., Ltd. Approves Election of Wang Ruwei as A Non-Executive Director

May 08, 2024 at 04:29 pm IST

Jiangsu Recbio Technology Co., Ltd. announced at the AGM held on May 8, 2024, approved Election of Dr. WANG Ruwei as a Non-executive Director of the Second Session of the Board.

Latest news about Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd. Approves Election of Wang Ruwei as A Non-Executive Director	08/05	CI
Jiangsu Recbio Technology Co., Ltd. and Shanghai Rongsheng Biotech Co.,Ltd. Sign Strategic Cooperation Agreement on the New Adjuvant Vaccine Project	27/03	CI
Jiangsu Recbio Technology's Loss Narrows in 2023	21/03	MT
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
Jiangsu Recbio Technology Co., Ltd. Announces Positive Results in the Interim Analysis of the Clinical Trial of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 in the Philippines	29/12	CI
Jiangsu Recbio Logs Positive Results from Philippines Trial Of Shingles Vaccine	29/12	MT
Jiangsu Recbio Technology to Extend Validity Period of Share Sale	28/12	MT
Jiangsu Recbio Technology Co., Ltd.(SEHK:2179) added to S&P Global BMI Index	18/23/18	CI
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/23/25	CI
China Approves Recbio's Clinical Trial Application for Shingles Vaccine	27/23/27	MT
Jiangsu Recbio Technology Co., Ltd. Announces Acceptance of Clinical Trial Application for the Novel Adjuvanted Recombinant Shingles Vaccine REC610 in China and Overseas Clinical Trial Progress	26/23/26	CI
Jiangsu Recbio Technology Selected for Morgan Stanley Capital International China Small Cap Index	17/23/17	MT
Jiangsu Recbio Technology Co., Ltd. Announces Directorate Appointments	11/23/11	CI
Chinese Securities Regulator Approves Jiangsu Recbio Technology's Share Issuance; Stock Sinks 3%	20/23/20	MT
Pfizer signs strategic cooperation pact with China's Sinopharm	13/23/13	RE
Jiangsu Recbio Technology Co., Ltd. Announces Resignation of Feng Tao as Non-Executive Director and A Member of the Nomination Committee	03/23/03	CI
Certain H Shares of Jiangsu Recbio Technology Co., Ltd. are subject to a Lock-Up Agreement Ending on 30-MAR-2023.	30/23/30	CI
Mongolia Grants Emergency Approval for Jiangsu Recbio's Recombinant COVID-19 Vaccine	21/23/21	MT
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
Jiangsu Recbio Technology Co., Ltd. Announces Resignation of Directors	20/23/20	CI
Jiangsu Recbio Completes Subject Enrollment for Vaccine Clinical Trial	13/23/13	MT
Jiangsu Recbio Technology Co., Ltd. Announces Completion of the First Batch of Subject Enrollment for the Phase I Clinical Trial of Novel Adjuvanted Recombinant Shingles Vaccine REC610	13/23/13	CI
China's Securities Regulator Accepts Jiangsu Recbio's Application for Shares Issuance	09/23/09	MT
Merck's COVID treatment expected to launch in China on Friday	11/23/11	RE
Jiangsu Recbio Receives Positive Results for Phase II Study of COVID-19 Vaccine in the Philippines	27/22/27	MT

Chart Jiangsu Recbio Technology Co., Ltd.

Duration

Period

Chart Jiangsu Recbio Technology Co., Ltd.

More charts

Jiangsu Recbio Technology Co Ltd is a China-based company mainly engaged in the research and development of vaccines. The Company has a portfolio of clinical-stage and pre-clinical stage vaccines, and its human papilloma virus (HPV) vaccine pipelines comprise of recombinant HPV 9-valent vaccine REC603, recombinant HPV 9-valent vaccines REC601 and REC602, recombinant HPV quadrivalent vaccine REC604a, and recombinant HPV 9-valent vaccine REC604b. The Company also involves in the development of Covid-19 vaccines. The Company mainly distributes products within domestic market.

Sector

Pharmaceuticals

Calendar

23/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

8.535 CNY

Average target price

11.99 CNY

Spread / Average Target

+40.45%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
JIANGSU RECBIO TECHNOLOGY CO., LTD.	-15.29%	568M
CSL LIMITED	-3.05%	90.45B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	41.45B
BIOGEN INC.	-10.66%	33.57B
UCB	+60.58%	25.73B
BIOMARIN PHARMACEUTICAL INC.	-20.71%	14.73B
INCYTE CORPORATION	-8.97%	12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.46%	11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.05%	11.44B
SWEDISH ORPHAN BIOVITRUM AB	+5.17%	8.79B

Biopharmaceuticals